PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 6090736-6 1984 Complete remission was obtained by CHOP therapy (consisting of cyclophosphamide, adriamycin, vincristine, and prednisolone) combined with cervical irradiation. Doxorubicin 81-91 DNA damage inducible transcript 3 Homo sapiens 35-39 3167803-6 1988 Employing CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) and consolidation radiation therapy in most cases, 80% achieved a complete remission and 59% survive failure-free at 5 years by actuarial calculation. Doxorubicin 47-58 DNA damage inducible transcript 3 Homo sapiens 10-14 3751969-2 1986 A 30-year-old woman with Stage IIIA diffuse non-Hodgkins lymphoma was treated with doxorubicin, cyclophosphamide, vincristine, and prednisone (CHOP) every 3 weeks. Doxorubicin 83-94 DNA damage inducible transcript 3 Homo sapiens 143-147 3840280-2 1985 We have reported a case of diffuse, poorly differentiated lymphocytic lymphoma, stage IIIa, in a patient whose disease went into remission after she received six courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone). Doxorubicin 205-216 DNA damage inducible transcript 3 Homo sapiens 173-177 6396563-2 1984 Chemotherapy with cyclophosphamide, vincristine and prednisone (COP) yielded partial response, but the addition of adriamycin (CHOP) a complete remission. Doxorubicin 115-125 DNA damage inducible transcript 3 Homo sapiens 127-131 33688781-1 2021 Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Doxorubicin 109-120 DNA damage inducible transcript 3 Homo sapiens 151-155 6950800-5 1982 Combination chemotherapy with cyclophosphamide, Doxorubicin, vincristine, and prednisone (CHOP) has produced impressive clinical responses in patients with PL. Doxorubicin 48-59 DNA damage inducible transcript 3 Homo sapiens 90-94 33857568-4 2021 Increased DDIT3 in these Dox-treated cardiomyocytes at 24h suggested that increased MitoBax may have promoted ER stress related changes in DDIT3. Doxorubicin 25-28 DNA damage inducible transcript 3 Homo sapiens 10-15 33857568-4 2021 Increased DDIT3 in these Dox-treated cardiomyocytes at 24h suggested that increased MitoBax may have promoted ER stress related changes in DDIT3. Doxorubicin 25-28 DNA damage inducible transcript 3 Homo sapiens 139-144 33857568-6 2021 In contrast, breast cancer MCF7 cells showed an ER stress response to Dox with increased DDIT3 as early as 3h which may have triggered a positive feedback activation of ATF6 at 12 and 24h and promoted Calnexin. Doxorubicin 70-73 DNA damage inducible transcript 3 Homo sapiens 89-94 33857568-8 2021 DDIT3 response in tumors was evoked by Dox, however this response was inversely correlated with increased Bip and Bax expression in hearts from tumor bearing animals. Doxorubicin 39-42 DNA damage inducible transcript 3 Homo sapiens 0-5 33857568-9 2021 It is suggested that in Dox-induced cardiotoxicity both mitochondrial and ER stresses play an integral role through a mutual interaction where an inhibition of DDIT3 or Calnexin may also be crucial to achieve Dox resistance in cardiomyocytes. Doxorubicin 24-27 DNA damage inducible transcript 3 Homo sapiens 160-165 33857568-9 2021 It is suggested that in Dox-induced cardiotoxicity both mitochondrial and ER stresses play an integral role through a mutual interaction where an inhibition of DDIT3 or Calnexin may also be crucial to achieve Dox resistance in cardiomyocytes. Doxorubicin 209-212 DNA damage inducible transcript 3 Homo sapiens 160-165 33555941-1 2021 PURPOSE: Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype. Doxorubicin 69-80 DNA damage inducible transcript 3 Homo sapiens 113-117 6697295-4 1984 A few hours after initiation of chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisolone (CHOP regimen), the patient developed an acute ascending paralysis. Doxorubicin 68-78 DNA damage inducible transcript 3 Homo sapiens 125-129 33734921-1 2021 BACKGROUND: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal. Doxorubicin 56-67 DNA damage inducible transcript 3 Homo sapiens 100-104 33436910-5 2021 The median AUCs of DXR and CPA were significantly smaller in the (R-)miniCHOP group than in the (R-)CHOP group (168.7 vs. 257.9 ng h/mL, P = 0.003, and 219.9 vs. 301.7 microg h/mL, P = 0.020, respectively). Doxorubicin 19-22 DNA damage inducible transcript 3 Homo sapiens 73-77 33592897-8 2021 INTERVENTIONS: The patient was first treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Doxorubicin 72-83 DNA damage inducible transcript 3 Homo sapiens 114-118 33348022-3 2021 This article reviews several chemical compounds that have been shown to regulate DOX-induced inflammation, apoptosis, and autophagy via inhibition of ER stress signaling pathways, such as the IRE1alpha/ASK1/JNK, IRE1alpha/JNK/Beclin-1, and CHOP pathways. Doxorubicin 81-84 DNA damage inducible transcript 3 Homo sapiens 240-244 33625586-1 2021 BACKGROUND: A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. Doxorubicin 62-73 DNA damage inducible transcript 3 Homo sapiens 106-110 33269174-3 2020 Recent studies have demonstrated a potential benefit with combination of dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-REPOCH) in comparison to standard combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in ABC DLBCL patients. Doxorubicin 156-167 DNA damage inducible transcript 3 Homo sapiens 296-300 33317571-1 2020 As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Doxorubicin 82-93 DNA damage inducible transcript 3 Homo sapiens 43-47 33323828-1 2020 Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. Doxorubicin 57-68 DNA damage inducible transcript 3 Homo sapiens 109-113 33230132-2 2020 The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Doxorubicin 89-100 DNA damage inducible transcript 3 Homo sapiens 30-34 33091357-1 2020 The integration of rituximab (R) into cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) by Coiffier and colleagues was the first, and last, successful modification of this backbone regimen, which has endured now for almost 20 years. Doxorubicin 56-67 DNA damage inducible transcript 3 Homo sapiens 98-102 33116822-6 2020 Subsequently, the patient was treated by six cycles of CHOP (cyclophosphamide + doxorubicin + vincristine + hydroprednisone) regimens. Doxorubicin 80-91 DNA damage inducible transcript 3 Homo sapiens 55-59 32730183-1 2020 PURPOSE: Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 66-77 DNA damage inducible transcript 3 Homo sapiens 110-114 32042095-3 2020 In current study, we aimed to explore the association between gene networks and overall survival (OS) of DLBCL patients treated with CHOP-based chemotherapy (cyclophosphamide combination with doxorubicin, vincristine and prednisone). Doxorubicin 192-203 DNA damage inducible transcript 3 Homo sapiens 133-137 32648457-1 2020 BACKGROUND: The CHOP regimen comprising cyclophosphamide, doxorubicin, vincristine, and prednisone is a basic chemotherapeutic regimen for diffuse large B cell lymphoma (DLBCL). Doxorubicin 58-69 DNA damage inducible transcript 3 Homo sapiens 16-20 32915975-2 2020 Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evidence is lacking to define fracture incidence in this group. Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 14-18 33093947-3 2020 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Doxorubicin 37-48 DNA damage inducible transcript 3 Homo sapiens 2-6 32250167-1 2020 While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Doxorubicin 50-61 DNA damage inducible transcript 3 Homo sapiens 93-97 32417940-2 2020 Progression or relapse of FL within 2 years (so-called POD24) after diagnosis is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) in clinical trials. Doxorubicin 179-190 DNA damage inducible transcript 3 Homo sapiens 140-144 32505213-1 2020 BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 91-95 32187361-11 2020 The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification. Doxorubicin 117-128 DNA damage inducible transcript 3 Homo sapiens 82-86 32112707-5 2020 In a small sample size, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) achieved better outcomes than a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Doxorubicin 78-89 DNA damage inducible transcript 3 Homo sapiens 231-235 31774307-11 2020 However, downstream signaling of eIF2alpha (activating transcription factor 4 and CCAAT/enhancer-binding protein homologous protein) was diminished in the heart but upregulated in the diaphragm with DOX. Doxorubicin 199-202 DNA damage inducible transcript 3 Homo sapiens 82-131 31852157-11 2019 INTERVENTIONS: The current first-line treatment for diffuse large B-cell lymphoma is the cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) protocol. Doxorubicin 107-117 DNA damage inducible transcript 3 Homo sapiens 144-148 31902733-4 2020 Our findings demonstrate good outcomes following induction treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), suggesting that these cases can be treated as DLBCL rather than primary central nervous system lymphoma, obviating the need for more aggressive and toxic approaches. Doxorubicin 111-122 DNA damage inducible transcript 3 Homo sapiens 76-80 31185769-2 2019 Among 65% of patients receiving treatment after diagnosis, R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) was the most common frontline therapy, increasing with more recent treatment year: 51% (2001-2003) vs. 69% (2010-2014). Doxorubicin 96-107 DNA damage inducible transcript 3 Homo sapiens 61-65 31543772-3 2019 We present a case of newly diagnosed Graves" thyrotoxicosis following a successful R-CHOP (Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone) treatment in a patient with concurrent abdominal and thyroid diffuse large B-cell lymphoma (DLBCL). Doxorubicin 120-132 DNA damage inducible transcript 3 Homo sapiens 85-89 31314918-1 2019 OBJECTIVES: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 14-18 31222719-1 2019 Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2-5% of patents with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 84-95 DNA damage inducible transcript 3 Homo sapiens 49-53 30850561-1 2019 BACKGROUND: About one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after receiving first-line (1L) treatment of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Doxorubicin 165-176 DNA damage inducible transcript 3 Homo sapiens 209-213 31801186-8 2019 Analysis of single CHOP compounds demonstrated that similar changes could also be induced by doxorubicin or vincristine, providing evidence for clinical combination therapies of doxorubicin or vincristine with BH3-mimetics in DLBCL. Doxorubicin 93-104 DNA damage inducible transcript 3 Homo sapiens 19-23 31801186-8 2019 Analysis of single CHOP compounds demonstrated that similar changes could also be induced by doxorubicin or vincristine, providing evidence for clinical combination therapies of doxorubicin or vincristine with BH3-mimetics in DLBCL. Doxorubicin 178-189 DNA damage inducible transcript 3 Homo sapiens 19-23 31832222-1 2019 Background: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. Doxorubicin 30-41 DNA damage inducible transcript 3 Homo sapiens 74-78 31118164-2 2019 The use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could overcome these difficulties, but blood-brain barrier (BBB) penetration of related drugs is poor. Doxorubicin 48-59 DNA damage inducible transcript 3 Homo sapiens 13-17 31280230-7 2019 Among 125 patients receiving CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, complete response and complete control were increased in patients receiving triple antiemetics, compared to those with double antiemetics. Doxorubicin 35-46 DNA damage inducible transcript 3 Homo sapiens 29-33 30313105-6 2018 The patient was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Neurological symptoms improved with R-CHOP. Doxorubicin 58-69 DNA damage inducible transcript 3 Homo sapiens 146-150 31516154-4 2019 He was managed by the oncologist with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen which alleviated his symptoms considerably after completion of three cycles and was under follow-up. Doxorubicin 75-86 DNA damage inducible transcript 3 Homo sapiens 40-44 30101910-1 2018 Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose for elderly patients remains unclear. Doxorubicin 69-80 DNA damage inducible transcript 3 Homo sapiens 21-25 30788202-10 2018 The patient was treated with six courses of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab). Doxorubicin 70-81 DNA damage inducible transcript 3 Homo sapiens 44-48 30431571-4 2018 INTERVENTIONS AND OUTCOMES: Fortunately, the patient"s skin lesions subsided gradually after 3 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Doxorubicin 123-134 DNA damage inducible transcript 3 Homo sapiens 167-171 30552901-0 2019 2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP. Doxorubicin 50-60 DNA damage inducible transcript 3 Homo sapiens 101-105 30552901-7 2019 Moreover, CHOP was remarkably elevated in the combination group, and silencing of CHOP almost completely blocked the apoptosis induced by the combination of 2-bromopalmitate and adriamycin. Doxorubicin 178-188 DNA damage inducible transcript 3 Homo sapiens 10-14 30552901-7 2019 Moreover, CHOP was remarkably elevated in the combination group, and silencing of CHOP almost completely blocked the apoptosis induced by the combination of 2-bromopalmitate and adriamycin. Doxorubicin 178-188 DNA damage inducible transcript 3 Homo sapiens 82-86 30340554-1 2018 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Doxorubicin 75-86 DNA damage inducible transcript 3 Homo sapiens 119-123 30172345-1 2018 BACKGROUND: Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. Doxorubicin 65-76 DNA damage inducible transcript 3 Homo sapiens 109-113 29380942-1 2018 The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP). Doxorubicin 163-174 DNA damage inducible transcript 3 Homo sapiens 176-180 29333403-1 2017 Background: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities. Doxorubicin 36-47 DNA damage inducible transcript 3 Homo sapiens 80-84 30071836-4 2018 CASE PRESENTATION: We present a patient with a history of Mantle cell lymphoma and treatment with R-CHOP (rituximab, doxorubicine, vincristine, cyclofosfamide, prednisone), with a meningo-encephalitis, who was treated for a suspected lymphoma relapse. Doxorubicin 117-129 DNA damage inducible transcript 3 Homo sapiens 100-104 28524259-10 2018 Nonpegylated liposomal doxorubicin instead of doxorubicin in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen is a feasible option for patients with diffuse large B-cell lymphoma presenting with concomitant cardiac disorders. Doxorubicin 23-34 DNA damage inducible transcript 3 Homo sapiens 67-71 28870016-8 2017 The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission. Doxorubicin 79-90 DNA damage inducible transcript 3 Homo sapiens 73-77 28791403-10 2017 Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease. Doxorubicin 126-137 DNA damage inducible transcript 3 Homo sapiens 91-95 28522441-2 2017 We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. Doxorubicin 54-65 DNA damage inducible transcript 3 Homo sapiens 98-102 28725161-1 2017 BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). Doxorubicin 54-65 DNA damage inducible transcript 3 Homo sapiens 95-99 26449182-1 2017 The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 4-8 26449182-1 2017 The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Doxorubicin 62-65 DNA damage inducible transcript 3 Homo sapiens 4-8 28445949-6 2017 These cells survived longer following treatment with a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Doxorubicin 88-99 DNA damage inducible transcript 3 Homo sapiens 129-133 28461685-6 2017 She received treatment with steroids, rituximab, cyclophosphamide, vincristine, and doxorubicin (R-CHOP). Doxorubicin 84-95 DNA damage inducible transcript 3 Homo sapiens 99-103 28559645-7 2017 TREATMENT AND OUTCOME: The patient had a good initial response to a CHOP scheme (cyclophosphamide, doxorubicin, vincristine and prednisone) with filgrastim. Doxorubicin 99-110 DNA damage inducible transcript 3 Homo sapiens 68-72 28096087-6 2017 Longitudinal analysis of plasma samples collected under rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) chemotherapy showed a rapid clearance of DLBCL mutations from cfDNA among responding patients. Doxorubicin 83-94 DNA damage inducible transcript 3 Homo sapiens 121-125 29212067-2 2017 Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Doxorubicin 95-106 DNA damage inducible transcript 3 Homo sapiens 139-143 27928587-1 2017 Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy has been mostly applied to patients with untreated peripheral T cell lymphoma (PTCL). Doxorubicin 18-29 DNA damage inducible transcript 3 Homo sapiens 62-66 28205354-3 2017 We take this opportunity to report a case of a 65 year-old man who developed a rapidly progressive glomerulonephritis within days after completing his first cycle of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) chemotherapy for newly diagnosed mantle cell lymphoma. Doxorubicin 203-214 DNA damage inducible transcript 3 Homo sapiens 168-172 27960150-2 2017 The use of the anthracycline doxorubicin has been associated with arrhythmias and cardiomyopathy, making patients with cardiac dysfunction poor candidates for R-CHOP. Doxorubicin 29-40 DNA damage inducible transcript 3 Homo sapiens 161-165 29279550-7 2017 Patients with ALK-positive ALCL are usually treated with anthracycline-based regimens, such as combination cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOEP (CHOP plus etoposide), which provide a favorable prognosis, except in patients with multiple International Prognostic Index factors. Doxorubicin 125-136 DNA damage inducible transcript 3 Homo sapiens 169-173 27913503-1 2016 Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ~30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Doxorubicin 42-53 DNA damage inducible transcript 3 Homo sapiens 86-90 28978846-6 2017 From recent prospective trials, conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen, which is the current standard regimen for DLBCL, has been acknowledged as a well-established regimen for DLBCL. Doxorubicin 82-93 DNA damage inducible transcript 3 Homo sapiens 47-51 28030899-8 2016 In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). Doxorubicin 57-68 DNA damage inducible transcript 3 Homo sapiens 209-213 27382104-1 2016 PURPOSE: Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Doxorubicin 224-235 DNA damage inducible transcript 3 Homo sapiens 200-204 26834485-7 2016 CONCLUSION: It is generally believed that the regimen consisting of cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, and prednisolone (CHOP) is also applicable to ALCL. Doxorubicin 86-105 DNA damage inducible transcript 3 Homo sapiens 152-156 27073670-1 2016 The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non-Hodgkin"s lymphoma (NHL). Doxorubicin 22-33 DNA damage inducible transcript 3 Homo sapiens 65-69 27342502-1 2016 OBJECTIVE: To explore the clinical efficiency and safety of CHOP regimen containing pegylated liposomal doxorubicin (PLD) for the aged patients with advanced diffuse large B-cell lymphoma (DLBCL). Doxorubicin 104-115 DNA damage inducible transcript 3 Homo sapiens 60-64 27188649-1 2016 BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Doxorubicin 45-56 DNA damage inducible transcript 3 Homo sapiens 89-93 27188649-1 2016 BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Doxorubicin 45-56 DNA damage inducible transcript 3 Homo sapiens 149-153 24675549-1 2016 This article describes the first reported case of dramatic lymphocytosis flare after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy for an indolent lymphoma. Doxorubicin 136-147 DNA damage inducible transcript 3 Homo sapiens 101-105 26986862-5 2016 We present a patient with T/myeloid mixed-phenotype acute leukemia secondary to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma. Doxorubicin 109-120 DNA damage inducible transcript 3 Homo sapiens 152-156 27039799-1 2016 BACKGROUND: A combination of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat B-cell non-Hodgkin"s lymphoma (NHL). Doxorubicin 60-71 DNA damage inducible transcript 3 Homo sapiens 104-108 26986862-11 2016 We describe a case of therapy-related T/myeloid mixed phenotype acute leukemia following rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma DLBCL. Doxorubicin 118-129 DNA damage inducible transcript 3 Homo sapiens 161-165 25666327-4 2015 We present a 52-year-old male with lymphoma who was treated with R-CHOP (R: Rituximab; C: Cyclophosphamide; H: Doxorubicin; O: Vincristine; P: Prednisone). Doxorubicin 111-122 DNA damage inducible transcript 3 Homo sapiens 67-71 26885255-2 2015 The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refractory to the R-CHOP regimen. Doxorubicin 58-68 DNA damage inducible transcript 3 Homo sapiens 101-105 26458444-2 2015 The current standard therapy for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which allows many patients to achieve disease cure. Doxorubicin 79-90 DNA damage inducible transcript 3 Homo sapiens 44-48 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Doxorubicin 48-59 DNA damage inducible transcript 3 Homo sapiens 92-96 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Doxorubicin 48-59 DNA damage inducible transcript 3 Homo sapiens 206-210 26370464-1 2015 BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin"s lymphoma (NHL). Doxorubicin 45-56 DNA damage inducible transcript 3 Homo sapiens 89-93 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Doxorubicin 125-136 DNA damage inducible transcript 3 Homo sapiens 166-170 25648098-1 2015 PURPOSE: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Doxorubicin 42-53 DNA damage inducible transcript 3 Homo sapiens 86-90 26076798-2 2015 Historically, PTCL was treated like aggressive B-cell lymphomas, and to date cyclophosphamide, prednisone, vincristine, and doxorubicin (CHOP) remains the most commonly used regimen, despite disappointing results. Doxorubicin 124-135 DNA damage inducible transcript 3 Homo sapiens 137-141 26334344-1 2015 INTRODUCTION: R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). Doxorubicin 70-81 DNA damage inducible transcript 3 Homo sapiens 16-20 25899891-0 2015 Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases. Doxorubicin 23-34 DNA damage inducible transcript 3 Homo sapiens 55-59 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Doxorubicin 69-80 DNA damage inducible transcript 3 Homo sapiens 113-117 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Doxorubicin 69-80 DNA damage inducible transcript 3 Homo sapiens 229-233 25445468-0 2015 Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Doxorubicin 20-31 DNA damage inducible transcript 3 Homo sapiens 81-85 25960846-9 2015 Also our study showed that controlled CINV episodes in patients who received CMF regimen were better than the regimen including adriamycin (CAF, CHOP) into both granisetron (p=0.06) and metoclopramid (p=0.04). Doxorubicin 128-138 DNA damage inducible transcript 3 Homo sapiens 145-149 25635435-1 2015 BACKGROUND: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 60-71 DNA damage inducible transcript 3 Homo sapiens 102-106 25459253-2 2014 We report the effect of a combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) for immunocompetent patients with PCNSL. Doxorubicin 90-101 DNA damage inducible transcript 3 Homo sapiens 135-139 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Doxorubicin 125-136 DNA damage inducible transcript 3 Homo sapiens 226-230 25177375-9 2014 CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease. Doxorubicin 196-207 DNA damage inducible transcript 3 Homo sapiens 242-246 25360516-2 2014 Here, we show that induction in cell surface GRP78 by doxorubicin and tunicamycin was associated with CHOP/GADD153 upregulation and increase in apoptosis in triple negative breast cancer tumor cells. Doxorubicin 54-65 DNA damage inducible transcript 3 Homo sapiens 102-106 25360516-2 2014 Here, we show that induction in cell surface GRP78 by doxorubicin and tunicamycin was associated with CHOP/GADD153 upregulation and increase in apoptosis in triple negative breast cancer tumor cells. Doxorubicin 54-65 DNA damage inducible transcript 3 Homo sapiens 107-114 25229255-2 2014 Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Doxorubicin 125-136 DNA damage inducible transcript 3 Homo sapiens 169-173 25325035-1 2014 BACKGROUND: Although adding rituximab to the chemotherapy regimen of cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) has improved clinical outcomes of patients with diffuse large B-cell lymphoma (DLBCL), several recent studies have shown that the effect of rituximab is dominantly in the non-germinal center (non-GC) subtype compared to the germinal center (GC) subtype. Doxorubicin 100-111 DNA damage inducible transcript 3 Homo sapiens 131-135 24289107-4 2014 This exploratory study was designed to correlate the mRNA expression levels of candidate genes mainly involved in the doxorubicin pathway (ABCB1, GSTP1, TOPO2alpha, BCL2, PKCbetaII) with the outcome of 54 patients with DLBCL undergoing a dose-dense R-CHOP regimen. Doxorubicin 118-129 DNA damage inducible transcript 3 Homo sapiens 251-255 25337281-5 2014 The patient was treated with 6 courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone), which resulted in complete remission (CR). Doxorubicin 74-85 DNA damage inducible transcript 3 Homo sapiens 42-46 24423982-2 2014 Here, we quantified the growth inhibition rate of a panel of clinically approved anticancer drugs in a patient-derived DLBCL cell line that is resistant to doxorubicin, a central component of the standard of care R-CHOP. Doxorubicin 156-167 DNA damage inducible transcript 3 Homo sapiens 215-219 25054764-7 2014 R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment. Doxorubicin 58-69 DNA damage inducible transcript 3 Homo sapiens 2-6 25042202-1 2014 BACKGROUND: Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Doxorubicin 141-152 DNA damage inducible transcript 3 Homo sapiens 185-189 25197420-5 2014 The patient was treated with chemotherapeutic regimens-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). Doxorubicin 79-90 DNA damage inducible transcript 3 Homo sapiens 55-59 24428090-1 2013 OBJECTIVE: To determine the effectiveness and tolerability of the combination of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with the addition of etoposide (CHOEP-21) for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs). Doxorubicin 117-128 DNA damage inducible transcript 3 Homo sapiens 161-165 24493716-1 2014 PURPOSE: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggressive B-cell lymphoma. Doxorubicin 50-61 DNA damage inducible transcript 3 Homo sapiens 11-15 24724408-3 2014 The current standard of care for DLBCL is CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with rituximab, anti-CD20 antibody, allowing many patients to achieve disease cure. Doxorubicin 79-90 DNA damage inducible transcript 3 Homo sapiens 42-46 22548975-2 2013 The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Doxorubicin 158-169 DNA damage inducible transcript 3 Homo sapiens 75-79 23846384-2 2013 The BM infiltration and the condition of the MF improved following CHOP therapy (cyclophosphamide hydrate, doxorubicin hydrochloride, vincristine sulfate, and prednisolone). Doxorubicin 107-132 DNA damage inducible transcript 3 Homo sapiens 67-71 23636313-7 2013 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Doxorubicin 125-136 DNA damage inducible transcript 3 Homo sapiens 167-171 23711089-0 2013 Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin. Doxorubicin 143-154 DNA damage inducible transcript 3 Homo sapiens 169-173 24143112-1 2013 Fludarabine-based regimens and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens with or without rituximab are the most common treatment modalities for indolent lymphoma. Doxorubicin 37-48 DNA damage inducible transcript 3 Homo sapiens 31-35 23670255-2 2013 Previously, we identified GADD153 as a target of BRCA1 protein, which increases doxorubicin sensitivity in human p53 -/- PCa cells (PC3). Doxorubicin 80-91 DNA damage inducible transcript 3 Homo sapiens 26-33 23670255-4 2013 METHODS: We performed reverse transcription quantitative PCR (RT-qPCR), western blot and luciferase assays to analyze GADD153 and/or BRCA1 expression in response to ultraviolet or doxorubicin exposure in PC3 p53 stable-transfected cells and LNCaP (p53+/+) cells. Doxorubicin 180-191 DNA damage inducible transcript 3 Homo sapiens 118-125 23670255-8 2013 RESULTS: We found that GADD153 was highly induced by doxorubicin in PC3 cells; however, this response was totally abolished in LNCaP (p53wt) and in p53-restituted PC3 cells. Doxorubicin 53-64 DNA damage inducible transcript 3 Homo sapiens 23-30 23137070-3 2013 Patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) had significantly superior survival rates. Doxorubicin 51-62 DNA damage inducible transcript 3 Homo sapiens 94-98 23578722-1 2013 BACKGROUND: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. Doxorubicin 68-79 DNA damage inducible transcript 3 Homo sapiens 112-116 24649228-2 2013 The reported 5-year overall survival for patients with localized nasal NKTCL treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP) is <50%. Doxorubicin 108-127 DNA damage inducible transcript 3 Homo sapiens 153-157 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Doxorubicin 73-84 DNA damage inducible transcript 3 Homo sapiens 117-121 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Doxorubicin 73-84 DNA damage inducible transcript 3 Homo sapiens 236-240 23394581-1 2013 Diffuse large B-cell lymphoma primary of lung (DLBCL-PL) is a rare presentation of extranodal lymphoma, in most cases chemotherapy-based anthracyclines: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the treatment, with excellent outcome. Doxorubicin 177-188 DNA damage inducible transcript 3 Homo sapiens 153-157 23598937-3 2013 We present a case of a 54-year-old man, diagnosed with non-Hodgkin lymphoma who received a first cycle of rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisolone (R-CHOP) chemotherapy 10 days prior presenting. Doxorubicin 156-167 DNA damage inducible transcript 3 Homo sapiens 209-213 23166041-2 2013 The CHOP chemotherapy regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone, has been used previously to treat other types of lymphomas. Doxorubicin 76-87 DNA damage inducible transcript 3 Homo sapiens 4-8 22972488-1 2013 PURPOSE: Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al. Doxorubicin 85-96 DNA damage inducible transcript 3 Homo sapiens 113-117 23053189-1 2013 R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. Doxorubicin 61-71 DNA damage inducible transcript 3 Homo sapiens 2-6 23996885-4 2013 We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Doxorubicin 104-115 DNA damage inducible transcript 3 Homo sapiens 62-66 24072968-8 2013 A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. Doxorubicin 131-142 DNA damage inducible transcript 3 Homo sapiens 92-96 24200545-8 2013 The patient received R-CHOP therapy (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) with good response. Doxorubicin 55-66 DNA damage inducible transcript 3 Homo sapiens 23-27 22865806-4 2012 A brain biopsy confirmed the diagnosis of intravascular B-cell lymphoma and he was treated with CHOP chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone). Doxorubicin 133-152 DNA damage inducible transcript 3 Homo sapiens 96-100 22759738-4 2012 SUMMARY: Rituximab administered as induction or maintenance therapy in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival. Doxorubicin 106-117 DNA damage inducible transcript 3 Homo sapiens 148-152 23814970-2 2012 Standard chemotherapy is CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). Doxorubicin 57-68 DNA damage inducible transcript 3 Homo sapiens 25-29 21460380-3 2012 The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Doxorubicin 52-63 DNA damage inducible transcript 3 Homo sapiens 93-97 22035416-1 2012 The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. Doxorubicin 96-106 DNA damage inducible transcript 3 Homo sapiens 136-140 22160255-1 2012 The purpose of the study is to evaluate the 10 years follow-up of the efficacy in Chinese patients receiving cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) regimen as the initial treatment for diffuse large B cell lymphoma (DLBCL). Doxorubicin 127-138 DNA damage inducible transcript 3 Homo sapiens 180-184 22203419-7 2012 Pretreatment with sodium hydrosulfide (NaHS, a H(2)S donor) before DOX exposure markedly suppressed DOX-induced overexpressions of GRP78 and CHOP, cytotoxicity and oxidative stress. Doxorubicin 100-103 DNA damage inducible transcript 3 Homo sapiens 141-145 21850390-13 2012 We conclude that replacing conventional doxorubicin with PLD in polychemotherapy regimens such as CHOP is an efficient alternative in the treatment of patients with preexisting cardiac dysfunction. Doxorubicin 40-51 DNA damage inducible transcript 3 Homo sapiens 98-102 22260632-4 2012 The patient initially received 6 cycles of chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin, prednisone), but his symptoms did not disappear. Doxorubicin 106-116 DNA damage inducible transcript 3 Homo sapiens 61-65 22260632-9 2012 CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in partial response of the disease with pancytopenia and suppression of cellular immunity. Doxorubicin 39-50 DNA damage inducible transcript 3 Homo sapiens 0-4 21851218-7 2011 In the current study generation, the addition of high-dose Ara-C to a rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival. Doxorubicin 99-110 DNA damage inducible transcript 3 Homo sapiens 142-146 21864040-1 2012 In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. Doxorubicin 107-118 DNA damage inducible transcript 3 Homo sapiens 150-154 23323070-8 2012 The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. Doxorubicin 58-77 DNA damage inducible transcript 3 Homo sapiens 105-109 21907693-1 2011 Activation of the endoplasmic reticulum (ER) stress pathway is associated with poor response to doxorubicin-containing regimens, such as rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine and prednisone (R-CHOP), in patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 96-107 DNA damage inducible transcript 3 Homo sapiens 231-235 22586509-2 2011 The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Doxorubicin 22-33 DNA damage inducible transcript 3 Homo sapiens 64-68 22586511-1 2011 Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has long been a standard treatment for lymphoma. Doxorubicin 36-47 DNA damage inducible transcript 3 Homo sapiens 78-82 22586511-2 2011 Improvements to the efficacy of this regimen can be made by increasing the doses of doxorubicin and cyclophosphamide, as in the chemotherapeutic regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP), and by reducing the standard dosing interval, as seen with the CHOP-14 regimen. Doxorubicin 84-95 DNA damage inducible transcript 3 Homo sapiens 296-300 21700680-0 2011 BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Doxorubicin 36-47 DNA damage inducible transcript 3 Homo sapiens 19-26 21931035-1 2011 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma. Doxorubicin 42-53 DNA damage inducible transcript 3 Homo sapiens 86-90 21472389-3 2011 She was treated with 4 cycles of CHOP chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine, and prednisolone at 4-week intervals. Doxorubicin 65-76 DNA damage inducible transcript 3 Homo sapiens 33-37 21257672-1 2011 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. Doxorubicin 75-86 DNA damage inducible transcript 3 Homo sapiens 119-123 21700680-8 2011 Finally, GADD153 depletion significantly abrogates BRCA1 influence on cell-cycle progression and cell death in response to doxorubicin treatment. Doxorubicin 123-134 DNA damage inducible transcript 3 Homo sapiens 9-16 21498532-1 2011 UNLABELLED: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 14-18 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 59-70 DNA damage inducible transcript 3 Homo sapiens 101-105 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 59-70 DNA damage inducible transcript 3 Homo sapiens 123-127 21944785-4 2011 Chemotherapy in the form of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisolone) is considered to be the first line of treatment for these lymphomas. Doxorubicin 66-85 DNA damage inducible transcript 3 Homo sapiens 31-35 21323512-1 2011 Development of resistance to the CHOP chemotherapeutic regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) remains a major cause of treatment failure and mortality in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 82-93 DNA damage inducible transcript 3 Homo sapiens 33-37 20542986-1 2010 PURPOSE: This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Doxorubicin 171-181 DNA damage inducible transcript 3 Homo sapiens 208-212 21482186-3 2011 We aimed to investigate the efficacy and safety of a decreased dose of CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisone) chemotherapy with a conventional dose of rituximab in elderly patients with diffuse large B-cell lymphoma. Doxorubicin 77-88 DNA damage inducible transcript 3 Homo sapiens 71-75 22099932-7 2011 AIM: The aim of the study was to evaluate the clinical risk stratification models including the age adjusted International prognostic index (aaIPI), patients profile and dose intensity (DI) of Cyclophosphamide and Doxorubicin as effective tools for predicting the outcome and prognosis of our DLBCL patients treated with first line CHOP regimen. Doxorubicin 214-225 DNA damage inducible transcript 3 Homo sapiens 332-336 22454706-5 2011 He received chemotherapy with CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisolone) resulting in reduction in lesion size leaving a phthysical eyeball and a ptotic lid. Doxorubicin 62-72 DNA damage inducible transcript 3 Homo sapiens 30-34 21050687-8 2010 The classic CHOP protocol (combination of doxorubicin-cyclophosphamide-vincristine-prednisone) does not have satisfactory results and survival remains poor, especially in patients with underlying RCD. Doxorubicin 42-53 DNA damage inducible transcript 3 Homo sapiens 12-16 20561333-1 2010 BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) has primarily been treated with cyclophosphamide, doxorubicin, vincristine, and predisone (CHOP) chemotherapy since the 1970s. Doxorubicin 100-111 DNA damage inducible transcript 3 Homo sapiens 141-145 21030533-3 2010 DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Doxorubicin 138-149 DNA damage inducible transcript 3 Homo sapiens 180-184 20830228-1 2010 BACKGROUND/AIMS: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). Doxorubicin 50-61 DNA damage inducible transcript 3 Homo sapiens 107-111 19861288-1 2009 Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Doxorubicin 33-44 DNA damage inducible transcript 3 Homo sapiens 76-80 20610938-1 2010 We report the case of a patient with non-Hodgkin"s lymphoma who, during chemotherapy according to the r-CHOP schedule (rituximab-cyclophosphamide-doxorubicin-vincristine and prednisone), showed a hepatic flare with jaundice. Doxorubicin 146-157 DNA damage inducible transcript 3 Homo sapiens 104-108 19850640-2 2010 cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Doxorubicin 18-29 DNA damage inducible transcript 3 Homo sapiens 59-63 20016232-2 2009 Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. Doxorubicin 51-62 DNA damage inducible transcript 3 Homo sapiens 27-31 19074749-1 2009 BACKGROUND: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. Doxorubicin 173-184 DNA damage inducible transcript 3 Homo sapiens 214-218 19204436-5 2009 There was significant improvement in response to the first 4 cycles of CHOP chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone) instituted, but then there were features of relapse. Doxorubicin 122-133 DNA damage inducible transcript 3 Homo sapiens 71-75 18420078-5 2008 Following combined chemotherapy with rituximab and mini-CHOP (cyclophosphamide, adriamycin, oncovin and prednisone), complete remission was obtained rapidly, with no relapse at two years. Doxorubicin 80-90 DNA damage inducible transcript 3 Homo sapiens 56-60 18502831-1 2008 Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Doxorubicin 71-81 DNA damage inducible transcript 3 Homo sapiens 108-112 17997372-10 2008 Subsequently, he underwent five cycles of CHOP (cyclofosfamide, doxorubicin, vincristin, prednison) chemotherapy with further partial regression of the abdominal tumour. Doxorubicin 64-75 DNA damage inducible transcript 3 Homo sapiens 42-46 18388378-7 2008 The patient received five cycles of a cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen which resulted in the regression in her skin lesions and constitutional symptoms. Doxorubicin 56-67 DNA damage inducible transcript 3 Homo sapiens 97-101 18712992-4 2008 The patient was treated with 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Doxorubicin 79-90 DNA damage inducible transcript 3 Homo sapiens 42-46 17031689-1 2007 Although adding rituximab to standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is an efficacious and well-tolerated regimen in elderly patients with diffuse large B cell lymphoma (DLBCL), it may increase susceptibility to opportunistic infections, and such cases have been reported. Doxorubicin 56-67 DNA damage inducible transcript 3 Homo sapiens 98-102 18415035-7 2008 Cumulative doxorubicin doses were 280 and 286 mg/m(2) on CHOP and R-CHOP (P = 0.65), respectively. Doxorubicin 11-22 DNA damage inducible transcript 3 Homo sapiens 57-61 18415035-7 2008 Cumulative doxorubicin doses were 280 and 286 mg/m(2) on CHOP and R-CHOP (P = 0.65), respectively. Doxorubicin 11-22 DNA damage inducible transcript 3 Homo sapiens 68-72 17939339-5 2007 A CT scan performed following three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) showed that the mass had nearly disappeared. Doxorubicin 82-93 DNA damage inducible transcript 3 Homo sapiens 126-130 17591563-3 2007 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy has been the standard systemic therapy for this disease with a cure rate of 40% to 50%, although, more recently, the addition of rituximab has been shown in phase III trials to confer a significant survival benefit in both older and younger patients. Doxorubicin 18-29 DNA damage inducible transcript 3 Homo sapiens 60-64 17488991-5 2007 However, response rate is usually lower in elderly patients compared with young patients, even if the patients are treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Doxorubicin 150-161 DNA damage inducible transcript 3 Homo sapiens 192-196 18306483-2 2008 Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Doxorubicin 118-129 DNA damage inducible transcript 3 Homo sapiens 68-72 18162120-1 2008 Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma. Doxorubicin 42-52 DNA damage inducible transcript 3 Homo sapiens 95-99 18226581-1 2008 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma. Doxorubicin 30-41 DNA damage inducible transcript 3 Homo sapiens 74-78 17912235-3 2008 By achieving selective, targeted, and early inhibition of NF-kappaB activity, we demonstrate that NF-kappaB plays a critical role in Dox-induced chemoresistance by regulating genes involved in proliferation (Ki-67), response to DNA damage (GADD153), antiapoptosis (Bcl-XL), and pH regulation (CA9). Doxorubicin 133-136 DNA damage inducible transcript 3 Homo sapiens 240-247 18284716-1 2007 Among the strategies developed to improve results in patients with diffuse large B-cell lymphoma, increasing the dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen (dose-intense regimen) and decreasing the duration of cycles (dose-dense regimen) or doing both had been proposed before the rituximab era. Doxorubicin 144-155 DNA damage inducible transcript 3 Homo sapiens 121-125 17530014-5 2007 A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Doxorubicin 73-84 DNA damage inducible transcript 3 Homo sapiens 113-117 16943530-2 2006 This conclusion is mainly derived from patients with mixed international prognostic index (IPI) risk profiles treated with CHOP-like therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Doxorubicin 160-171 DNA damage inducible transcript 3 Homo sapiens 123-127 16788784-5 2006 The standard chemotherapy for aggressive non-Hodgkin"s lymphomas is the CHOP regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Doxorubicin 117-128 DNA damage inducible transcript 3 Homo sapiens 72-76 17085516-4 2006 The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population. Doxorubicin 126-137 DNA damage inducible transcript 3 Homo sapiens 88-92 17027654-4 2006 Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. Doxorubicin 96-107 DNA damage inducible transcript 3 Homo sapiens 138-142 16985248-1 2006 BACKGROUND: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. Doxorubicin 84-95 DNA damage inducible transcript 3 Homo sapiens 126-130 16416337-1 2006 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Doxorubicin 47-58 DNA damage inducible transcript 3 Homo sapiens 89-93 16093797-5 2005 Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma. Doxorubicin 27-38 DNA damage inducible transcript 3 Homo sapiens 79-83 16575475-1 2006 Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin s lymphoma, is associated with the presence of an early impairment of cardiac function. Doxorubicin 100-111 DNA damage inducible transcript 3 Homo sapiens 68-72 16575475-14 2006 The results show that subclinical cardiac impairment was frequent in patients receiving the CHOP regimen with safe cumulative doses of doxorubicin. Doxorubicin 135-146 DNA damage inducible transcript 3 Homo sapiens 92-96 16640819-3 2006 In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin"s lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen. Doxorubicin 204-215 DNA damage inducible transcript 3 Homo sapiens 181-185 15666323-1 2005 BACKGROUND: The standard treatment for patients with aggressive non-Hodgkin lymphoma (NHL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Doxorubicin 112-123 DNA damage inducible transcript 3 Homo sapiens 154-158 16158823-8 2005 We first treated the patient with fludarabine and then with the CHOP regimen (cyclophosphamide, hydroxydaunomycin, vincristine [Oncovin], and prednisone), but the disease was so refractory that the patient died of the disease 13 months after the splenectomy. Doxorubicin 96-113 DNA damage inducible transcript 3 Homo sapiens 64-68 15791475-3 2005 The patient was treated for diffuse large B-cell non-Hodgkin"s lymphoma with CHOP therapy (doxorubicin, cyclophosphamide, vincristine, and prednisone). Doxorubicin 91-102 DNA damage inducible transcript 3 Homo sapiens 77-81 15955905-1 2005 PURPOSE: For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). Doxorubicin 54-65 DNA damage inducible transcript 3 Homo sapiens 96-100 16006279-1 2005 Treatment of non-Hodgkin"s lymphoma with the CHOP regimen consists of intravenous cyclophosphamide 750 mg/m2 (day 1), intravenous doxorubicin 50 mg/m2 (day 1), intravenous vincristine 1.4 mg/m2 (day 1), and oral prednisone 100 mg (days 1-5). Doxorubicin 130-141 DNA damage inducible transcript 3 Homo sapiens 45-49 14982884-1 2004 The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. Doxorubicin 37-48 DNA damage inducible transcript 3 Homo sapiens 100-104 15794864-2 2005 Cyclophosphamide/doxorubicin/vincristine/prednisone/rituximab (CHOP-R) is a stem cellsparing regimen that has been extensively evaluated in patients without WM or non-Hodgkin"s lymphoma. Doxorubicin 17-28 DNA damage inducible transcript 3 Homo sapiens 63-67 15621841-5 2005 The patient responded to chemotherapy with CHOP (doxorubicin, cyclophosphamide, vincristine and prednisone) therapy, with disappearance of the abnormal clone from the bone marrow. Doxorubicin 49-60 DNA damage inducible transcript 3 Homo sapiens 43-47 17532718-4 2005 METHODS: A decision-analysis model described clinical events and economic consequences for theoretical patients who were to receive eight consecutive cycles of a CHOP regimen containing 50 mg/m(2) of doxorubicin as first-line chemotherapy. Doxorubicin 200-211 DNA damage inducible transcript 3 Homo sapiens 162-166 15550586-1 2004 BACKGROUND: We demonstrated that highly active antiretroviral therapy (HAART) increases the toxic effect of cyclophosphamide, vincristine, doxorubicin (DOX) and prednisone (CHOP) in HIV-patients with non-Hodgkin"s lymphoma (NHL). Doxorubicin 152-155 DNA damage inducible transcript 3 Homo sapiens 173-177 15550586-7 2004 Significant associations (P=0.012) were observed between DOX AUC0-infinity (area under the concentration curve) and G3-G4 WHO haematologic toxicity, in patients treated with CHOP alone, but not in those treated with CHOP + HAART (P = not significant). Doxorubicin 57-60 DNA damage inducible transcript 3 Homo sapiens 174-178 15550586-7 2004 Significant associations (P=0.012) were observed between DOX AUC0-infinity (area under the concentration curve) and G3-G4 WHO haematologic toxicity, in patients treated with CHOP alone, but not in those treated with CHOP + HAART (P = not significant). Doxorubicin 57-60 DNA damage inducible transcript 3 Homo sapiens 216-220 15550586-9 2004 DOX AUC appears to be a predictor of toxicity only in patients treated with CHOP alone. Doxorubicin 0-3 DNA damage inducible transcript 3 Homo sapiens 76-80 15550586-10 2004 Other factors beside DOX plasma levels are detrimental for toxicity after CHOP + HAART. Doxorubicin 21-24 DNA damage inducible transcript 3 Homo sapiens 74-78 15060745-2 2004 The risk is significantly evident in patients with aggressive lymphoma, which is highly responsive to standard chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) achieving a complete response rate of 60-80% and 5-year survival rate of 30-50% with only 1% of treatment-related mortality. Doxorubicin 147-164 DNA damage inducible transcript 3 Homo sapiens 195-199 15181605-5 2004 In patients with aggressive lymphoma who receive cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, 40% to 70% of patients attain a complete remission, depending on risk factors such as age and extranodal involvement. Doxorubicin 67-78 DNA damage inducible transcript 3 Homo sapiens 109-113 15205203-2 2004 Recently, chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) has been reported as effective treatment for early-stage gastric DLBCL. Doxorubicin 37-48 DNA damage inducible transcript 3 Homo sapiens 96-100 15042528-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Doxorubicin 50-61 DNA damage inducible transcript 3 Homo sapiens 13-17 28140109-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Doxorubicin 50-61 DNA damage inducible transcript 3 Homo sapiens 13-17 14604284-5 2003 Because of an allergic reaction to L-asparaginase, 6 courses of CHOP (adriamycin, cyclophosphamide, vincristine and prednisolone) therapy were administered as consolidation after 4 courses of L-asparaginase. Doxorubicin 70-80 DNA damage inducible transcript 3 Homo sapiens 64-68 14752912-4 2004 Current chemotherapy of choice is CHOP [Cyclophosphamide, Hydroxydaunomycin (doxorubicin), Oncovin (vincristine sulfate) and Prednisone]. Doxorubicin 58-75 DNA damage inducible transcript 3 Homo sapiens 34-38 14752912-4 2004 Current chemotherapy of choice is CHOP [Cyclophosphamide, Hydroxydaunomycin (doxorubicin), Oncovin (vincristine sulfate) and Prednisone]. Doxorubicin 77-88 DNA damage inducible transcript 3 Homo sapiens 34-38 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Doxorubicin 83-94 DNA damage inducible transcript 3 Homo sapiens 142-146 12956443-10 2003 In this study, the t(11;16) was seen in 2 patients with previous lymphomas treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Doxorubicin 106-117 DNA damage inducible transcript 3 Homo sapiens 148-152 14581895-1 2003 BACKGROUND: Six to eight cycles of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard for intermediate-grade non-Hodgkin"s lymphoma (NHL) but is associated with toxicity that may cause premature termination of therapy. Doxorubicin 67-78 DNA damage inducible transcript 3 Homo sapiens 35-39 12764549-9 2003 Cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP)-like chemotherapy with or without local irradiation led to 17% relapses in patients with localized aggressive lymphoma. Doxorubicin 18-35 DNA damage inducible transcript 3 Homo sapiens 66-70 14988743-10 2003 Impressive results have been seen in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in follicular and high-grade lymphomas. Doxorubicin 91-102 DNA damage inducible transcript 3 Homo sapiens 54-58 12707721-2 2003 During pregnancy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) stabilized the disease for 4 months before new manifestations appeared. Doxorubicin 53-64 DNA damage inducible transcript 3 Homo sapiens 95-99 12490805-7 2002 Eventually the patient responded to CHOP (cyclophosphamide, Oncovin [vincristine, Eli Lilly, Indianapolis, IN], prednisone, and doxorubicin) therapy. Doxorubicin 128-139 DNA damage inducible transcript 3 Homo sapiens 36-40 12710585-5 2002 The most significant of these strategies is the combination of rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), which is proving a highly effective combination in the treatment of NHL. Doxorubicin 114-125 DNA damage inducible transcript 3 Homo sapiens 77-81 12222701-3 2002 If this disease could be diagnosed earlier, therapy with chlorpropamide, doxorubicin, vincristine and prednisone (CHOP) could bring about a remission (2,3,4). Doxorubicin 73-84 DNA damage inducible transcript 3 Homo sapiens 114-118 12176789-1 2002 BACKGROUND: Recent data suggest that chemotherapy with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen is a highly effective treatment for localised primary gastric lymphoma of diffuse large B-cell histology (DLBCL). Doxorubicin 77-88 DNA damage inducible transcript 3 Homo sapiens 118-122 12479593-3 2002 The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Doxorubicin 109-120 DNA damage inducible transcript 3 Homo sapiens 150-154 12168880-0 2002 Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin"s lymphoma. Doxorubicin 20-31 DNA damage inducible transcript 3 Homo sapiens 39-43 11807147-1 2002 BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Doxorubicin 104-115 DNA damage inducible transcript 3 Homo sapiens 146-150 12091638-20 2002 The CHOP regimen is cyclophosphamide, doxorubicine, vincristine and prednisone. Doxorubicin 38-50 DNA damage inducible transcript 3 Homo sapiens 4-8 11584710-9 2001 Standard treatment of advanced aggressive NHL is polychemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Doxorubicin 89-99 DNA damage inducible transcript 3 Homo sapiens 129-133 11878581-1 2001 PURPOSE: The authors report the use of a cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP)-based chemotherapy regimen in treating six children with posttransplantation lymphoproliferative disorder (PTLD) that developed after solid organ transplantation. Doxorubicin 59-78 DNA damage inducible transcript 3 Homo sapiens 109-113 10173030-3 1997 One such treatment that is considered to have a low potential for inducing fever and neutropenia is the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) for non-Hodgkin"s lymphoma. Doxorubicin 136-147 DNA damage inducible transcript 3 Homo sapiens 104-108 11699226-16 2001 We conclude that the substitution of DaunoXome for doxorubicin in the CHOP regimen to form COP-X provides excellent efficacy against non-Hodgkin"s lymphoma. Doxorubicin 51-62 DNA damage inducible transcript 3 Homo sapiens 70-74 9649147-3 1998 CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary toxicity. Doxorubicin 32-43 DNA damage inducible transcript 3 Homo sapiens 0-4 11230885-1 2001 BACKGROUND: A limited number cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy followed by involved field radiotherapy is the treatment of choice for Ann Arbor stage I intermediate or high grade non-Hodgkin"s lymphomas (NHL). Doxorubicin 57-68 DNA damage inducible transcript 3 Homo sapiens 98-102 9647875-1 1998 BACKGROUND: Patients with clinically localized, intermediate- or high-grade non-Hodgkin"s lymphoma usually receive initial treatment with a doxorubicin-containing regimen such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Doxorubicin 140-151 DNA damage inducible transcript 3 Homo sapiens 239-243 9752311-1 1998 The CHOP regimen (cyclophosphamide vincristine, adriamycin, prednisone) is considered since twenty years as the standard treatment of disseminated aggressive non-Hodgkin"s lymphomas and cures approximately 30% of patients. Doxorubicin 48-58 DNA damage inducible transcript 3 Homo sapiens 4-8 8688344-1 1996 A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin"s lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Doxorubicin 35-46 DNA damage inducible transcript 3 Homo sapiens 78-82 9115450-3 1997 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is well tolerated in patients who have a good performance status and who have aggressive histology lymphoma, but briefer 8-week regimens appear to offer similar benefits more quickly. Doxorubicin 18-29 DNA damage inducible transcript 3 Homo sapiens 60-64 8523055-3 1995 The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen. Doxorubicin 96-107 DNA damage inducible transcript 3 Homo sapiens 202-206 8629263-5 1996 The CHOP-regime, consisting of doxorubicin, cyclophosphamide, oncovin and prednisolon, is the standard therapy that should be given outside of clinical trials. Doxorubicin 31-42 DNA damage inducible transcript 3 Homo sapiens 4-8 7595704-13 1995 Treatment with CHOP (doxorubicin) results in better CR and survival rates than CNOP (mitoxantrone). Doxorubicin 21-32 DNA damage inducible transcript 3 Homo sapiens 15-19 7898521-5 1995 METHODS: To investigate whether patients with slow responses, defined as only a partial response after three courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), would benefit from early transplantation, we conducted a prospective, randomized trial. Doxorubicin 138-149 DNA damage inducible transcript 3 Homo sapiens 180-184 7680764-1 1993 BACKGROUND: CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin"s lymphoma in national cooperative-group trials. Doxorubicin 105-116 DNA damage inducible transcript 3 Homo sapiens 12-16 8038494-13 1993 In a previous randomized trial, the French Co-operative Group on CLL showed a beneficial role for low-dose adriamycin given with cyclophosphamide, vincristine and prednisone (mini-CHOP) in patients with stage C disease. Doxorubicin 107-117 DNA damage inducible transcript 3 Homo sapiens 180-184 8369658-11 1993 Our successful treatment is radiation therapy combined with six courses of CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine, prednisolone). Doxorubicin 112-122 DNA damage inducible transcript 3 Homo sapiens 75-79 8236992-1 1993 In a group of 30 patients with the diagnosis of malignant non-Hodgkin lymphoma of high histological malignancy, a prospective randomized study was carried out concerning the effectiveness and toxicity of the CHOP chemotherapy using adriamycin vs epirubicin. Doxorubicin 232-242 DNA damage inducible transcript 3 Homo sapiens 208-212 1630019-6 1992 The patient was treated with the CHOP regimen (doxorubicin, cyclophosphamide, vincristine and prednisolone), which achieved complete remission. Doxorubicin 47-58 DNA damage inducible transcript 3 Homo sapiens 33-37 1383819-8 1992 The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. Doxorubicin 67-78 DNA damage inducible transcript 3 Homo sapiens 132-136 8469201-6 1993 TREATMENT AND OUTCOME: After initial response to CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone), she relapsed and died with central nervous system involvement eight months after the initial diagnosis. Doxorubicin 86-97 DNA damage inducible transcript 3 Homo sapiens 49-53 2246824-6 1990 After chemotherapy using adriamycin, cyclophosphamide, vincristine, and prednisolone (CHOP), lymphadenopathy and splenomegaly reduced and lymphoid blasts disappeared from the blood and bone marrow. Doxorubicin 25-35 DNA damage inducible transcript 3 Homo sapiens 86-90 27463485-9 1991 It demonstrated that the polychemotherapy CHOP, i.e. COP + doxorubicin improved these patients (n = 34) as compared with those treated with COP (n = 36), in terms of disease remission as well as survival. Doxorubicin 59-70 DNA damage inducible transcript 3 Homo sapiens 42-46 1703327-10 1990 It was concluded that the alternate chemotherapy regimen CHOP-Bleo/CMED shows similar effects than the classical CHOP-Bleo treatment, and provides a lesser amount of adriamycin, which makes it feasible to use this or other anthracycline drugs in case of relapse; the use of this regimen must be borne in mind when the patient is carrying a myocardiopathy. Doxorubicin 166-176 DNA damage inducible transcript 3 Homo sapiens 57-61 2317752-4 1990 Continuous CHOP protocol consists of initial 8 weeks of intensive chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, followed by local/cranial radiotherapy and maintenance therapy. Doxorubicin 102-113 DNA damage inducible transcript 3 Homo sapiens 11-15 34990525-1 2021 Purpose: Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Doxorubicin 195-206 DNA damage inducible transcript 3 Homo sapiens 241-245 2182600-7 1990 In one large randomized study, the response rate as well as survival superiority of CHOP (with low-dose Adriamycin) over COP in previously untreated patients with stage C disease was observed. Doxorubicin 104-114 DNA damage inducible transcript 3 Homo sapiens 84-88 2182600-8 1990 In another large randomized study, only a response rate advantage of CHOP (with standard dose Adriamycin) over chlorambucil and prednisone (in previously untreated patients with stages B and C) was seen. Doxorubicin 94-104 DNA damage inducible transcript 3 Homo sapiens 69-73 33944646-5 2021 The main focus of this study was on newly diagnosed patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus other chemotherapy. Doxorubicin 89-100 DNA damage inducible transcript 3 Homo sapiens 131-135 33591324-1 2021 Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). Doxorubicin 32-43 DNA damage inducible transcript 3 Homo sapiens 70-74 34943000-5 2021 In vivo Dox treatment increased mitochondrial iNOS to promote ER stress as there was an increase in Bip (Grp78) response, proapoptotic CHOP (DDIT3) and ER-mediated Caspase 12 activation. Doxorubicin 8-11 DNA damage inducible transcript 3 Homo sapiens 135-139 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Doxorubicin 121-132 DNA damage inducible transcript 3 Homo sapiens 163-167 34943000-5 2021 In vivo Dox treatment increased mitochondrial iNOS to promote ER stress as there was an increase in Bip (Grp78) response, proapoptotic CHOP (DDIT3) and ER-mediated Caspase 12 activation. Doxorubicin 8-11 DNA damage inducible transcript 3 Homo sapiens 141-146 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Doxorubicin 198-209 DNA damage inducible transcript 3 Homo sapiens 241-245 34797531-1 2022 Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Doxorubicin 120-131 DNA damage inducible transcript 3 Homo sapiens 175-179 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Doxorubicin 198-209 DNA damage inducible transcript 3 Homo sapiens 254-258 34586105-2 2021 The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Doxorubicin 126-137 DNA damage inducible transcript 3 Homo sapiens 63-67 34745610-0 2021 Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Doxorubicin 169-180 DNA damage inducible transcript 3 Homo sapiens 209-213 34745610-1 2021 Objectives: A diverse intratumoral T-cell receptor (TCR) repertoire is associated with improved survival in diffuse large B-cell lymphoma (DLBCL) treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Doxorubicin 186-197 DNA damage inducible transcript 3 Homo sapiens 226-230 34765356-4 2021 We report a case of a 65-year-old man who presented with acutely worsening dyspnoea and stridor following his fifth cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for hematological malignancy. Doxorubicin 154-165 DNA damage inducible transcript 3 Homo sapiens 200-204 34362493-0 2021 (Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study). Doxorubicin 1-35 DNA damage inducible transcript 3 Homo sapiens 42-46 34362493-1 2021 OBJECTIVE: To evaluate the efficacy and safety of CHOP regimen based on doxorubicin hydrochloride liposome in the initial treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 72-97 DNA damage inducible transcript 3 Homo sapiens 50-54 34120620-4 2021 Unfortunately, DOX is the main cytotoxic drug in R-CHOP and it can lead to adverse reactions. Doxorubicin 15-18 DNA damage inducible transcript 3 Homo sapiens 51-55 35468783-1 2022 BACKGROUND: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. Doxorubicin 45-56 DNA damage inducible transcript 3 Homo sapiens 89-93 34124276-1 2021 The majority of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed or refractory disease after standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, which is partly related to a dysregulated tumor immune microenvironment. Doxorubicin 148-159 DNA damage inducible transcript 3 Homo sapiens 192-196 35573753-3 2022 We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. Doxorubicin 131-142 DNA damage inducible transcript 3 Homo sapiens 92-96 35089671-3 2022 Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard of care and cures more than 60% of patients. Doxorubicin 39-50 DNA damage inducible transcript 3 Homo sapiens 83-87 35451406-1 2022 ABSTRACT: Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Doxorubicin 84-95 DNA damage inducible transcript 3 Homo sapiens 128-132 35297262-13 2022 The patient received treatment with mini-CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) plus rituximab with partial response after the third cycle. Doxorubicin 78-89 DNA damage inducible transcript 3 Homo sapiens 41-45 35044836-1 2022 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) represents the standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Doxorubicin 42-53 DNA damage inducible transcript 3 Homo sapiens 88-92